Bulk Inquiry
ASP 3026
- Soluble in 0.1N HCl(aq) and DMSO
- MF: C29H40N8O3S
- MW: 580.74
Description
Selective inhibitor of the oncogenic fusion kinase EML4-ALK; ASP3026 has a broad safety margin and inhibitory activity at the gatekeeper mutation; potential agent in EML4-ALK fusion positive NSCLC patients, that have relapsed to Crizotinib (Axon 1660)
More Information
| Parent CAS No. | 1097917-15-1 |
|---|---|
| Chemical Name | N2-(2-(isopropylsulfonyl)phenyl)-N4-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-1,3,5-triazine-2,4-diamine |
| SMILES | N1=CN=C(NC2=CC=CC=C2S(C(C)C)(=O)=O)N=C1NC1=CC=C(N2CCC(N3CCN(C)CC3)CC2)C=C1OC |
| MFCD | MFCD21609265 |
| InChi | InChI=1S/C29H40N8O3S/c1-21(2)41(38,39)27-8-6-5-7-25(27)33-29-31-20-30-28(34-29)32-24-10-9-23(19-26(24)40-4)36-13-11-22(12-14-36)37-17-15-35(3)16-18-37/h5-10,19-22H,11-18H2,1-4H3,(H2,30,31,32,33,34) |
| InChiKey | MGGBYMDAPCCKCT-UHFFFAOYSA-N |
| CID | 25134326 |
| Short Description | ALK inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1416 | NVP-TAE684 |
From $55.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1884 | Alectinib |
From $77.00 |
| 2153 | AZD3463 |
From $115.50 |
| 2224 | LDK 378 |
From $104.50 |
| 2267 | GSK 1838705A |
From $121.00 |
| 2294 | KRCA 0008 |
From $104.50 |
| 2600 | PF 06463922 |
From $115.50 |
| 2978 | Brigatinib |
From $88.00 |
| 3931 | CEP-28122 |
From Inquiry |
| 3973 | XL-228 |
From Inquiry |
| 4038 | CEP-37440 hydrochloride |
From Inquiry |
